Schonfeld Strategic Advisors’s Revance Therapeutics, Inc. RVNC Stock Holding History

Schonfeld Strategic Advisors’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-100,000	Closed	-$519K	–	2483
2024 Q3	$519K	Buy	+100,000	New	+$497K	﹤0.01%	1414

Other funds holding RVNC

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Schonfeld Strategic Advisors's RVNC Position: Q1 2025 in Review

Schonfeld Strategic Advisors sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 13,400 shares — an estimated $40.7K sold.

Schonfeld Strategic Advisors first reported a position in RVNC in Q4 2017 and held it in 12 quarters. The position peaked at $5.86M in Q3 2022. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

Schonfeld Strategic Advisors reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
Schonfeld Strategic Advisors sold 13,400 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $40.7K.
Schonfeld Strategic Advisors first reported a position in Revance Therapeutics, Inc. in Q4 2017 and held it in 12 quarters.
Schonfeld Strategic Advisors's Revance Therapeutics, Inc. position peaked at $5.86M in Q3 2022.
1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2025, filed 15 May 2025.